Clinical Trial Update: A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP) [Phase 2]

View source ↗

Summary

This Phase 2a trial of BIVV020 in adults with persistent or chronic immune thrombocytopenia has completed, with results posted in February 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• BIVV020

Snippet

Sponsor: Bioverativ, a Sanofi company | Conditions: Immune Thrombocytopenia (ITP) | Phase 2 | Status: COMPLETED | Results posted: 2024-02-22